Previously, the BRAF V600E mutation focused on malignant tumours, where the prevalence was approximately 74.6% for papillary thyroid carcinoma [95], 7.4% for colorectal cancer [96], and 60% for melanomas [97]. This evidence concerns the gene BRAF and colorectal cancer.